Navamedic ASA · OSL:NAVA

Navamedic ASA — H1 2022 Earnings Presentation

26 slides from Navamedic ASA's earnings presentation, Aug 12, 2022

  1. Slide 1: Second quarter and first half year results 2022

    Q2/H1 2022 Second quarter and first half year results 2022 Navamedic ASA 12 August 2022 Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO 1

  2. Slide 2: Highlights

    Highlights Record high quarterly revenue and EBITDA Strong development for key focus areas: Obesity: Continued strong demand for Mysimba®, resolved the temporary out-of-stock situation in Q1 2022 REVENUE GROSS MARGIN EBITDA Gastro: Q2 110.4 MNOK 44.8% 23.7 MNOK The successful launch of gastro produc

  3. Slide 3: On track towards 20% Y/Y revenue growth target

    On track towards 20% Y/Y revenue growth target Consistent positive trend in revenue and EBITDA • Consistent strong revenue growth over time driven by positive market trends, successful build-up of new 350 000 +38% 35% categories, M&A and distribution partnerships 300 000 30% 250 000 25% • Normal flu

  4. Slide 4: Navamedic in brief

    Navamedic in brief Nordic pharma company targeting growth in Northern Europe A reliable supplier of high- Presence in all Nordic Strong local competence in Ambitious growth strategy, quality pharma products, countries, Baltics and regulatory, reimbursement, high-potential pipeline and delivered to h

  5. Slide 5: Strategic growth drivers

    Strategic growth drivers Ambition of building a NOK 1 billion revenue company Recent achievements 1 STRENGTHEN THE CORE Untapping potential within existing products, categories and territories. Ongoing negotiations for attractive new agreements 2 SECURE AND INCREASE THE VALUE THROUGH OWNERSHIP Innov

  6. Slide 6: Key portfolio developments

    Key portfolio developments Strong revenue development across portfolio MEDICAL CONSUMER BRANDED SPECIALTY NUTRITION HEALTH GENERICS PHARMA YTD 2022 revenue (YoY growth): 30.6 (19%) YTD 2022 revenue (YoY growth): 25.7 (32%) YTD 2022 revenue (YoY growth): 41.7 (29%) YTD 2022 revenue (YoY growth): 75.3

  7. Slide 7: Consumer Health

    Consumer Health Gastro category developing strongly, continued strong potential for Navamedic going forward Q2 2022 REVENUE GROWTH DRIVERS • IBS product Alflorex® and 14.8 MNOK pain product Thermacare® with solid growth during the (Q2 2021: 8.5 MNOK) quarter • Gastro – an underdeveloped sector in th

  8. Slide 8: Branded Generics

    Branded Generics Antibiotics portfolio with rapid growth, high innovation pace with new products to be introduced Q2 2022 REVENUE GROWTH DRIVERS 20.7 MNOK • Strong performance for the antibiotic portfolio (Q2 2021: 17.6 MNOK) • Imdur behind last year 8

  9. Slide 9: Medical Nutrition

    Medical Nutrition Key product area PKU continuing its steady growth GROWTH DRIVERS Q2 2022 REVENUE • Continued good growth for the key product area PKU 16.9 MNOK products (Q2 2021: 13.4 MNOK) • Small reduction in other products resulting in flat quarter for the medical nutrition category • New Modif

  10. Slide 10: Specialty Pharma

    Specialty Pharma Strong growth in obesity CONTINUED STRONG • Key product category for MYSIMBA WHOLESALE Navamedic with solid DEVELOPMENT expected growth going Q2 2022 REVENUE 130% increase from Q2 2021 – forward Norway is driving growth 57.9 MNOK • Out-of stock situation for Mysimba® in March-May, T

  11. Slide 11: The Impolin acquisition | Strategic rationale

    The Impolin acquisition | Strategic rationale Strengthens and complements Navamedic’s position within obesity in the Nordics • Impolin’s strong position in Sweden With Impolin’ product Modifast and MedMade, Navamedic supports weight will be further boosted by loss across the whole user journey Navam

  12. Slide 12: Financials

    FINANCIALS @ Navamedic

  13. Slide 13: Key consolidated profit and loss figures

    Financials The Q2 P&L includes one month of Impolin numbers Key consolidated profit and loss figures In Q2 2022, revenues grew by 67% compared to the same quarter last year (in NOK '1000) Q2 2022 Q2 2021 YTD 2022 YTD 2021 FY 2021 Operating revenues 110 361 66 014 173 357 124 659 278 439 Gross Profit

  14. Slide 14: Assets

    Financials Assets The increase in Goodwill is due to the (in NOK '1000) 30.06.2022 30.06.2021 31.12.2021 Impolin acquisition Goodwill 98 175 62 602 61 031 Deferred tax assets 9 168 9 168 9 168 Shares in associated companies is moved Other intangible assets 31 659 29 983 27 342 to financial assets as

  15. Slide 15: Equity and liabilities

    Financials Equity and liabilities (in NOK '1000) 30.06.2022 30.06.2021 31.12.2021 Equity ratio of 43.7% Total equity 185 692 148 894 151 237 Non-current license liabilities 6 039 8 385 8 171 The increase in Loans and borrowings Loans and borrowings 53 042 20 120 38 980 is due to the financing of the

  16. Slide 16: Cash flow Group – total operations

    Financials Cash flow Group – total operations (in NOK '1000) Q2 2022 Q2 2021 YTD 2022 YTD 2021 FY 2021 The cash flow from Operating Activities is mainly the result of Net profit coupled Net cash flow from operating activities 5 359 -4 322 -13 135 -16 756 -1 300 with changes in net working capital Ne

  17. Slide 17: Summary & Outlook

    SUMMARY & OUTLOOK 17 @ Navamedic

  18. Slide 18: Summary and outlook

    Navamedic ASA Summary and outlook Building a leading Nordic pharma company targeting growth in Northern Europe MID-TERM AMBITION Highlights 20% annual organic • Continued to strengthen the core by driving underlying growth in the existing portfolio • Strong growth in most product categories growth,

  19. Slide 19: Q&A

    Q&A @ Navamedic

  20. Slide 20: Thank you for your attention!

    Thank you for your attention! Navamedic’s Q3 2022 presentation will be on 1st of November 2022 20

  21. Slide 21: Appendix

    APPENDIX @ Navamedic

  22. Slide 22: The Impolin acquisition | About Impolin and Modifast

    The Impolin acquisition | About Impolin and Modifast Unique position in Sweden, great potential in the Nordics Impolin in short: • Unique position in Sweden with strong products and sales channels • Solid growth and profitability profile • Revenue 2021: SEK 52 million (+9.2% Y/Y) • 2021 EBIT margin:

  23. Slide 23: Condensed consolidated statement of comprehensive income

    Navamedic ASA Condensed consolidated statement of comprehensive income (in NOK '1000) Q2 2022 Q2 2021 YTD 2022 YTD 2021 FY 2021 Operating revenues 110 361 66 014 173 357 124 659 278 439 Total revenue 110 361 66 014 173 357 124 659 278 439 Cost of materials -60 893 -40 048 -99 054 -75 479 -166 695 Gr

  24. Slide 24: Condensed consolidated statement of cash flows

    Navamedic ASA Condensed consolidated statement of cash flows (in NOK '1000) Q2 2022 Q2 2021 YTD 2022 YTD 2021 FY 2021 Cash flow from operating activities Profit before tax 9 575 3 329 10 096 37 2 358 Adjusted for: Depreciation, amortization and impairment 1 830 1 380 3 660 2 722 6 716 Financial inco

  25. Slide 25: Basis for preparation and Alternative Performance Measures

    Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres

  26. Slide 26: Copyright and disclaimer

    Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any

Navamedic — H1 2022 Earnings Presentation on 6ix